AR076076A1 - FUSIONED BICYCLIC AND HETEROCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE TO PREPARE THEM, AND USE OF THEM IN THE TREATMENT OF INFLAMMATORY AND / OR AUTOIMMUNE DISEASES - Google Patents

FUSIONED BICYCLIC AND HETEROCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE TO PREPARE THEM, AND USE OF THEM IN THE TREATMENT OF INFLAMMATORY AND / OR AUTOIMMUNE DISEASES

Info

Publication number
AR076076A1
AR076076A1 ARP100100635A ARP100100635A AR076076A1 AR 076076 A1 AR076076 A1 AR 076076A1 AR P100100635 A ARP100100635 A AR P100100635A AR P100100635 A ARP100100635 A AR P100100635A AR 076076 A1 AR076076 A1 AR 076076A1
Authority
AR
Argentina
Prior art keywords
indicates
atoms
het1
cycloalkyl
hal
Prior art date
Application number
ARP100100635A
Other languages
Spanish (es)
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of AR076076A1 publication Critical patent/AR076076A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos de formula (1) para la regulacion de la actividad de las PI3K y enfermedades relacionadas. Reivindicacion 1: Un compuesto de acuerdo con la formula (1), en donde - - - - - indica un enlace simple o un enlace doble; U indica CRc, CH, o S; V indica C o N; W indica N o CR1; X indica CO, SO, SO2, CS o un enlace; Y indica CR2 o N; Ra indica NH-Ab, NA2, NH(CH2)p-Ab, -NH-(CH2)p-Ar, -NH(CH2)p-Het4, -NH-(CH2)pCHOR6-Het1, -NH-(CH2)pCOAr, -NH-(CH2)pCOHet1, -NH-cicloalquilo, COHet1, o un resto del grupo de formulas (2), o si X indica un enlace, también CO-N(H)2-m(A)m, CO, CS, o si X indica CO, SO, SO2, CS, también H, o si V indica C, también Ar o Het1, o si Rb es Ar, Het3, o uno de los restos del grupo de formulas (3), Ra también indica A, -(CH2)s-Ar, -(CH2)s-Het1, Het1, Het4, o perfluoroalquilo, o si Rb indica Ar, Ra es también -OA o cicloalquilo; Rb indica Ar, Het2, Het3 o un resto del grupo de formulas (3); R', R'' son independientemente hidrogeno, alquilo, Ar, Het1, Het2 o A; R' y R'' juntamente con el átomo de nitrogeno al que se encuentran fijados, pueden opcionalmente formar un anillo heterocíclico de 3-8 miembros; Rc indica H, A, alquilo, Ar, Het1; Ar indica un anillo carbocíclico aromático monocíclico o bicíclico que posee 6 a 14 átomos de carbono, que es insustituido o monosustituido, disustituido o trisustituido por, Hal, CF3, OCF3, NO2, CN, perfluoroalquilo, A, OA, OH, NH2, COH, CONH2, -NHCOA, -NHCO2A, NHCO2(CH2)sHet1, -(CH2)pHet1, -NHSO2A, -NHSO2-N(H)2-m(A)m, N(H)1-qAqCOA, N(H)1-qASO2N(H)2-m(A)m, N(H)1-qAqCON(H)2-m(A)m, COOA, COA, -SO2A, -SO2N(H)2-m(A)m, -SO2Het1, -SO2NHHet1, Het1, -NHSO2NHHet1, o cicloalquilo; Het1 indica un anillo monocíclico o bicíclico saturado o insaturado o aromático heterocíclico que posee 1 a 4 átomos N, O y/o S y/o 1 grupo CO, que es insustituido o monosustituido, disustituido o trisustituido por alquilo con 1 a 8 átomos de carbono, alcoxi con 1 a 8 átomos de carbono, Hal, CF3, OCF3, NO2, CN, perfluoroalquilo, A, OA, O(CH2)sAr, O(CH2)sHet1, -(CH2)pHet2, OH, amino, CONH2, NHCOA, -NHCO2A, -NHCO2(CH2)sAr, -NHSO2-N(H)2-m(A)m, COA, COOA, -SO2A, -SO2N(H)2-m(A)m, -SO2Het2, -SO2NHHet2, -NHSO2NHHet2, Ar, -NHSO2NHAr, -SO2NHAr, SO2Ar, cicloalquilo; Het2 indica un anillo monocíclico o bicíclico saturado, insaturado o aromático heterocíclico que posee 1 a 4 átomos N, O y/o S y/o 1 grupo CO, que es insustituido o monosustituido, disustituido o trisustituido por alquilo con 1 a 8 átomos de carbono, alcoxi con 1 a 8 átomos de carbono, Hal, CF3, OCF3, NO2, CN, perfluoroalquilo, A, OA, O(CH2)sAr, O(CH2)sHet1, -(CH2)pHet1, OH, NA2, CONH2, -NHCOA, -NHCO2A, -NHCO2(CH2)sHet1, -NHCO2(CH2)sAr, -NHSO2-N(H)2-m(A)m, COA, COOA, -SO2A, -SO2N(H)2-m(A)m, -SO2Het1, SO2NHHet2, Ar, SO2Ar, o cicloalquilo; Het3 indica un anillo monocíclico saturado, insaturado o aromático heterocíclico que posee 1 a 4 átomos N, O y/o S y/o 1 grupo CO, que es insustituido o monosustituido, disustituido o trisustituido por NO2, CN, perfluoroalquilo, OH, CONH2, -NHCOA, -NHCO2A, -NHCO2(CH2)sHet1, -NHCO2(CH2)sAr, -NHSO2A, -NHSO2-N(H)2-m(A)m, COA, COOA, -COH, -SO2A, SO2N(H)2-m(A)m, -SO2Het1, SO2NHHet2, o cicloalquilo o Het3 indica uno de los restos del grupo de formulas (4); Het4 indica un anillo monocíclico o bicíclico insaturado o aromático heterocíclico que posee 1 a 4 átomos N, O y/o S y/o 1 grupo CO, que es insustituido o monosustituido, disustituido o trisustituido por alquilo con 1 a 8 átomos de carbono, alcoxi con 1 a 8 átomos de carbono, Hal, CF3, OCF3, NO2, CN, perfluoroalquilo, A, OA, O(CH2)sAr, O(CH2)sHet1, -(CH2)pHet2, OH, amino, CONH2, -NHCOA, -NHCO2A, -NHCO2(CH2)sAr, -NHSO2-N(H)2-m(A)m, COA, COOA, -SO2A, -SO2N(H)2-m(A)m, -SO2Het2, -SO2NHHet2, NHSO2NHHet2, Ar, -NHSO2NHAr, -SO2NHAr, SO2Ar, cicloalquilo o Het4 indica uno de los restos del grupo de formulas (5); m indica 0, 1 o 2; n indica 1, 2, 3 o 4; p indica 0, 1, 2, 3, 4; q indica 0 o 1; s indica 1, 2, 3, 4; A es un alquilo ramificado o lineal que posee 1 a 12 átomos de carbono, en donde uno o más, preferentemente 1 a 7 átomos H pueden ser reemplazados por Hal, Ar, Het1, Het2, OR6, CN, NHCO, CONR'R'', COOR6 o NR'R'' y en donde uno o más, preferentemente 1 a 7 grupos CH2 no adyacentes pueden ser reemplazados por O, NR6 o S y/o por grupos -CH=CH- o -CsC-, o indica cicloalquilo, cicloalqueno o cicloalquilalquileno que posee 3-7 átomos de C de anillo en donde el cicloalquileno es opcionalmente sustituido por 1 o 2 grupos OH; Ab es un alquilo ramificado o lineal que posee 1 a 12 átomos de carbono, en donde uno o más, preferentemente 1 a 7 átomos H pueden ser reemplazados por Hal, Ar, OR6, CN, NHCO, CONR'R'', COOR6 o NR'R'' y en donde uno o más, preferentemente 1 a 7 grupos CH2 no adyacentes pueden ser reemplazados por grupos O, NR6 o S y/o por -CH=CH- o -CsC-, o indica cicloalquilo, cicloalqueno o cicloalquilalquileno que posee 3-7 átomos de C de anillo en donde el cicloalquileno es opcionalmente sustituido por 1 o 2 grupos OH; R1, R2 son cada uno independientemente H, Hal, CF3, A, Ar, Het1 o Het2; R3 es H o Hal; R', R'' denotan cada uno independientemente H, Ar, Het1, Het2, o A, y di R' o R'' se une a un átomo C también OA; R6 es H, un alquilo ramificado o lineal o hidroxialquilo que posee 1 a 12 átomos de carbono; y derivados, solvatos, tautomeros, sales y sus estereoisomeros farmacéuticamente aceptables, con inclusion de sus mezclas en todas las relaciones.Compounds of formula (1) for the regulation of the activity of PI3K and related diseases. Claim 1: A compound according to formula (1), wherein - - - - - indicates a single bond or a double bond; U indicates CRc, CH, or S; V indicates C or N; W indicates N or CR1; X indicates CO, SO, SO2, CS or a link; Y indicates CR2 or N; Ra indicates NH-Ab, NA2, NH (CH2) p-Ab, -NH- (CH2) p-Ar, -NH (CH2) p-Het4, -NH- (CH2) pCHOR6-Het1, -NH- (CH2 ) pCOAr, -NH- (CH2) pCOHet1, -NH-cycloalkyl, COHet1, or a remainder of the group of formulas (2), or if X indicates a bond, also CO-N (H) 2-m (A) m , CO, CS, or if X indicates CO, SO, SO2, CS, also H, or if V indicates C, also Ar or Het1, or if Rb is Ar, Het3, or one of the remains of the formula group (3 ), Ra also indicates A, - (CH2) s-Ar, - (CH2) s-Het1, Het1, Het4, or perfluoroalkyl, or if Rb indicates Ar, Ra is also -OA or cycloalkyl; Rb indicates Ar, Het2, Het3 or a remainder of the group of formulas (3); R ', R' 'are independently hydrogen, alkyl, Ar, Het1, Het2 or A; R 'and R' 'together with the nitrogen atom to which they are attached, can optionally form a 3-8 membered heterocyclic ring; Rc indicates H, A, alkyl, Ar, Het1; Ar indicates a monocyclic or bicyclic aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by, Hal, CF3, OCF3, NO2, CN, perfluoroalkyl, A, OA, OH, NH2, COH , CONH2, -NHCOA, -NHCO2A, NHCO2 (CH2) sHet1, - (CH2) pHet1, -NHSO2A, -NHSO2-N (H) 2-m (A) m, N (H) 1-qAqCOA, N (H ) 1-qASO2N (H) 2-m (A) m, N (H) 1-qAqCON (H) 2-m (A) m, COOA, COA, -SO2A, -SO2N (H) 2-m (A ) m, -SO2Het1, -SO2NHHet1, Het1, -NHSO2NHHet1, or cycloalkyl; Het1 indicates a saturated or unsaturated monocyclic or bicyclic or heterocyclic aromatic ring having 1 to 4 N, O and / or S atoms and / or 1 CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by alkyl with 1 to 8 atoms of carbon, alkoxy with 1 to 8 carbon atoms, Hal, CF3, OCF3, NO2, CN, perfluoroalkyl, A, OA, O (CH2) sAr, O (CH2) sHet1, - (CH2) pHet2, OH, amino, CONH2 , NHCOA, -NHCO2A, -NHCO2 (CH2) sAr, -NHSO2-N (H) 2-m (A) m, COA, COOA, -SO2A, -SO2N (H) 2-m (A) m, -SO2Het2 , -SO2NHHet2, -NHSO2NHHet2, Ar, -NHSO2NHAr, -SO2NHAr, SO2Ar, cycloalkyl; Het2 indicates a saturated, unsaturated or aromatic heterocyclic monocyclic or bicyclic ring having 1 to 4 N, O and / or S atoms and / or 1 CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by alkyl with 1 to 8 atoms of carbon, alkoxy with 1 to 8 carbon atoms, Hal, CF3, OCF3, NO2, CN, perfluoroalkyl, A, OA, O (CH2) sAr, O (CH2) sHet1, - (CH2) pHet1, OH, NA2, CONH2 , -NHCOA, -NHCO2A, -NHCO2 (CH2) sHet1, -NHCO2 (CH2) sAr, -NHSO2-N (H) 2-m (A) m, COA, COOA, -SO2A, -SO2N (H) 2- m (A) m, -SO2Het1, SO2NHHet2, Ar, SO2Ar, or cycloalkyl; Het3 indicates a saturated, unsaturated or aromatic heterocyclic monocyclic ring having 1 to 4 N, O and / or S atoms and / or 1 CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by NO2, CN, perfluoroalkyl, OH, CONH2 , -NHCOA, -NHCO2A, -NHCO2 (CH2) sHet1, -NHCO2 (CH2) sAr, -NHSO2A, -NHSO2-N (H) 2-m (A) m, COA, COOA, -COH, -SO2A, SO2N (H) 2-m (A) m, -SO2Het1, SO2NHHet2, or cycloalkyl or Het3 indicates one of the moieties of the group of formulas (4); Het4 indicates an unsaturated monocyclic or bicyclic or heterocyclic aromatic ring having 1 to 4 N, O and / or S atoms and / or 1 CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by alkyl with 1 to 8 carbon atoms, alkoxy with 1 to 8 carbon atoms, Hal, CF3, OCF3, NO2, CN, perfluoroalkyl, A, OA, O (CH2) sAr, O (CH2) sHet1, - (CH2) pHet2, OH, amino, CONH2, - NHCOA, -NHCO2A, -NHCO2 (CH2) sAr, -NHSO2-N (H) 2-m (A) m, COA, COOA, -SO2A, -SO2N (H) 2-m (A) m, -SO2Het2, -SO2NHHet2, NHSO2NHHet2, Ar, -NHSO2NHAr, -SO2NHAr, SO2Ar, cycloalkyl or Het4 indicates one of the remains of the formula group (5); m indicates 0, 1 or 2; n indicates 1, 2, 3 or 4; p indicates 0, 1, 2, 3, 4; q indicates 0 or 1; s indicates 1, 2, 3, 4; A is a branched or linear alkyl having 1 to 12 carbon atoms, wherein one or more, preferably 1 to 7 H atoms can be replaced by Hal, Ar, Het1, Het2, OR6, CN, NHCO, CONR'R ' ', COOR6 or NR'R' 'and where one or more, preferably 1 to 7 non-adjacent CH2 groups can be replaced by O, NR6 or S and / or by groups -CH = CH- or -CsC-, or indicates cycloalkyl, cycloalkene or cycloalkylalkylene having 3-7 ring C atoms wherein the cycloalkylene is optionally substituted by 1 or 2 OH groups; Ab is a branched or linear alkyl having 1 to 12 carbon atoms, wherein one or more, preferably 1 to 7 H atoms, can be replaced by Hal, Ar, OR6, CN, NHCO, CONR'R '', COOR6 or NR'R '' and wherein one or more, preferably 1 to 7 non-adjacent CH2 groups can be replaced by O, NR6 or S groups and / or by -CH = CH- or -CsC-, or indicates cycloalkyl, cycloalkene or cycloalkylalkylene having 3-7 ring C atoms wherein the cycloalkylene is optionally substituted by 1 or 2 OH groups; R1, R2 are each independently H, Hal, CF3, A, Ar, Het1 or Het2; R3 is H or Hal; R ', R' 'each independently denotes H, Ar, Het1, Het2, or A, and di R' or R '' is attached to a C atom also OA; R6 is H, a branched or linear alkyl or hydroxyalkyl having 1 to 12 carbon atoms; and derivatives, solvates, tautomers, salts and their pharmaceutically acceptable stereoisomers, including their mixtures in all relationships.

ARP100100635A 2009-03-04 2010-03-03 FUSIONED BICYCLIC AND HETEROCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE TO PREPARE THEM, AND USE OF THEM IN THE TREATMENT OF INFLAMMATORY AND / OR AUTOIMMUNE DISEASES AR076076A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09154345 2009-03-04
US23913709P 2009-09-02 2009-09-02

Publications (1)

Publication Number Publication Date
AR076076A1 true AR076076A1 (en) 2011-05-18

Family

ID=40577951

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100635A AR076076A1 (en) 2009-03-04 2010-03-03 FUSIONED BICYCLIC AND HETEROCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE TO PREPARE THEM, AND USE OF THEM IN THE TREATMENT OF INFLAMMATORY AND / OR AUTOIMMUNE DISEASES

Country Status (2)

Country Link
AR (1) AR076076A1 (en)
WO (1) WO2010100144A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2307400B1 (en) 2008-05-30 2014-04-23 Amgen, Inc Inhibitors of pi3 kinase
JP2011525535A (en) * 2008-06-24 2011-09-22 武田薬品工業株式会社 PI3K / mTOR inhibitor
EP2408773A2 (en) 2009-03-20 2012-01-25 Amgen, Inc Inhibitors of pi3 kinase
US9181234B2 (en) * 2010-10-08 2015-11-10 Biota Europe Ltd. Antibacterial compounds
WO2012174312A2 (en) * 2011-06-15 2012-12-20 Glaxosmithkline Llc Benzimidazole derivatives as antiviral agents
AP2014007595A0 (en) * 2011-09-30 2014-04-30 Kineta Inc Anti-viral compounds
KR20150033716A (en) 2012-07-10 2015-04-01 아레스 트레이딩 에스.에이. Pyrimidine pyrazolyl derivatives
WO2014083327A1 (en) * 2012-11-27 2014-06-05 Md Pharma Ab Adenine derivatives suitable for the treatment of (inter alia) muscular dystrophy
EP3066072B1 (en) * 2013-11-07 2021-11-03 The University of Kansas Biphenylamide derivative hsp90 inhibitors
US9598424B2 (en) 2014-03-06 2017-03-21 Takeda Pharmaceutical Company Limited Heteroarylamide inhibitors of TBK1
CN104402875A (en) * 2014-12-25 2015-03-11 西安山川医药科技有限公司 Synthesis method and application N-(2-aminoethyl)-N'-(6-substituted-2-benzothiazolyl)urea and salt compounds thereof
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
US10947225B2 (en) 2016-05-11 2021-03-16 Emory University Phosphotidylinositol 3-kinase inhibitors
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
CN107641118B (en) * 2016-07-22 2020-11-06 爱科诺生物医药股份有限公司 Compound with cell necrosis inhibition activity, composition and application thereof
WO2018237370A1 (en) * 2017-06-23 2018-12-27 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and method using the same
CN109111464B (en) * 2017-06-23 2021-02-26 爱科诺生物医药股份有限公司 Heterocyclic compound with cell necrosis inhibition activity
HUE062526T2 (en) 2017-10-02 2023-11-28 1St Biotherapeutics Inc Benzothiazol compounds and methods using the same for treating neurodegenerative disorders
US10508113B2 (en) 2018-03-12 2019-12-17 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
CN108558869B (en) * 2018-05-10 2019-04-09 西安培华学院 For treating the compound and its preparation of liver cancer
CN111434661B (en) * 2019-01-11 2023-09-12 爱科诺生物医药(香港)有限公司 Aromatic heterocyclic compound with cell necrosis inhibition activity and application thereof
WO2020170205A1 (en) 2019-02-22 2020-08-27 1ST Biotherapeutics, Inc. Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
KR20210126146A (en) 2019-03-07 2021-10-19 주식회사 퍼스트바이오테라퓨틱스 [ 18 F]-labeled benzothiazole derivatives as PET radiotracer
US10385046B1 (en) 2019-03-19 2019-08-20 1ST Biotherapeutics, Inc. Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders
KR20210134065A (en) * 2019-03-28 2021-11-08 주식회사 퍼스트바이오테라퓨틱스 Pharmaceutical salts, polymorphs and methods for their preparation of benzothiazole compounds
BR112022006977A2 (en) * 2019-10-11 2022-09-20 Incyte Corp BICYCLIC AMINES AS CDK2 INHIBITORS
US20230234967A1 (en) * 2020-05-28 2023-07-27 Senda Biosciences, Inc. Fused Azole Heterocycles as AHR Antagonists
AU2021347913A1 (en) 2020-09-28 2023-05-18 1ST Biotherapeutics, Inc. Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
WO2023012081A1 (en) 2021-08-05 2023-02-09 Syngenta Crop Protection Ag Method for controlling diamide resistant pests & compounds therefor
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473784B2 (en) * 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
PE20070978A1 (en) * 2006-02-14 2007-11-15 Novartis Ag HETEROCICLIC COMPOUNDS AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASES (PI3Ks)
WO2008119734A2 (en) * 2007-03-29 2008-10-09 Novartis Ag Process for the manufacture of organic compounds
JP5561702B2 (en) * 2007-08-02 2014-07-30 アムジエン・インコーポレーテツド PI3 kinase modulator and method of use

Also Published As

Publication number Publication date
WO2010100144A1 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
AR076076A1 (en) FUSIONED BICYCLIC AND HETEROCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE TO PREPARE THEM, AND USE OF THEM IN THE TREATMENT OF INFLAMMATORY AND / OR AUTOIMMUNE DISEASES
AR071523A1 (en) FUSIONATED BICYCLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, THE COMPOSITE TO BE USED AS A MEDICINAL PRODUCT IN THE TREATMENT AND PROFILAXIS OF DISEASES, A PHARMACEUTICAL COMPOSITION AND A SET THAT INCLUDES SEPARATE PACKAGES OF THE COMPOUND AND OF AN INGREDIENT
CO6170361A2 (en) COMPOSITIONS AND METHODS TO MODULATE C-KIT AND PDGFR RECEPTORS
UY29609A1 (en) BENZAMIDINE DERIVATIVES AND RELATED USES OF THE SAME
AR081626A1 (en) AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
AR035913A1 (en) IMIDAZOPIRIDINES REPLACED WITH PHENYLL, COMPOSITIONS THAT INCLUDE THEM AND USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES
ECSP045483A (en) DERIVATIVES OF BENZOCONDENSED HETEROARILAMIDE OF USEFUL TIENOPIRIDINS AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR USE
ES2606197T3 (en) GPR40 pyrrolidine modulators
AR052903A1 (en) BIS ARILO AND HETEROARILO COMPOUNDS REPLACED AS SELECTIVE ANTAGONISTS OF 5HT2A, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF SOIL DISORDERS.
AR057131A1 (en) PURINE DERIVATIVES AS IMMUNOMODULATOR
UY30141A1 (en) NEW POTENTIATING ISOINDOLONES OF METABOTROPIC GLUTAMATE RECEPTORS
AR056986A1 (en) AZA HETEROCICLOS AS INHIBITORS OF KINASES. PROCEDURE FOR OBTAINING AND PHARMACEUTICAL COMPOSITIONS
CO6210729A2 (en) DERIVATIVES OF SULFONIL-FENIL-2H- [1,2,4] OXADIAZOL-5-ONA PROCEDURES FOR PREPARATION AND USE AS A PHARMACEUTICAL AGENT
AR066669A1 (en) IMIDAZOLONA DERIVATIVES AS INHIBITORS OF BENCIMIDAZOLONA QUIMASA. PHARMACEUTICAL COMPOSITIONS.
EA201001013A1 (en) BIS (SULFONILAMINO) DERIVATIVES FOR USE IN THERAPY
AR084507A1 (en) INDAZOLILTRIAZOL DERIVATIVES
AR078320A1 (en) INHIBITING NITROGEN DERIVATIVES OF BRUTON TYPEOSINQUINASH INHIBITORS (BTK), PHARMACEUTICAL FORMULATIONS CONTAINING THEM AND USE OF THE SAME IN THE TREATMENT OF AUTOIMMUNE, INFLAMMATORY AND CANCERAL DISEASES.
AR075396A1 (en) DERIVATIVES OF KINAZOLINES AND PHARMACEUTICAL COMPOSITIONS
AR086367A1 (en) PIRROLIDINIL UREA AND PIRROLIDINIL TIOUREA COMPOUNDS AS TRKA CINASE INHIBITORS
CY1108908T1 (en) KINOLINONINE - CARBOXAMIDIS COMPOUNDS AS 5-HT4 RECEPTOR AGONS
AR058398A1 (en) DIAZEPINONES, PROCESSES OF OBTAINING, PHARMACEUTICAL COMPOSITIONS AND ITS USE AS INHIBITORS OF KINASES.
AR057906A1 (en) PIRIMIDONA DERIVATIVES REPLACED BICYCLES AND ITS USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE ABNORMAL ACTIVITY OF GSK3BETA.
AR072227A1 (en) SUBSTITUTED TRIAZINONA DERIVATIVES
AR060536A1 (en) GLUCOCORTICOID RECEPTOR AGONIST AND PHARMACEUTICAL COMPOSITIONS
AR050208A1 (en) COMPOSITE OF HETEROARIL SULFONAMIDE REPLACED, PROCEDURE FOR THE PREPARATION OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT

Legal Events

Date Code Title Description
FB Suspension of granting procedure